Moderna and Merck announced Wednesday that their personalized mRNA cancer vaccine, paired with Merck’s immunotherapy Keytruda, hit its main goal in a Phase 3 trial of 1,137 patients with surgically removed high-risk melanoma, cutting the rate of cancer recurrence and slowing distant spread compared to Keytruda alone. It’s the first positive late-stage trial result ever recorded for an individualized, mRNA-based cancer therapy. Wall Street’s reaction was immediate and extreme: Moderna’s stock jumped 177 percent in a single trading day, adding roughly $40 billion in market value and wiping out about $5.5 billion in paper losses for investors who had bet against the stock. Merck shares rose about 12 percent and hit a fresh 52-week high.
The rally didn’t hold. By the next day, Moderna’s stock had given back about a quarter of its gain, closing down 24 percent at $133.32, a reminder that a single-day trading spike driven by interim trial data is not the same thing as a settled, durable valuation.
A Real Medical Result, Wrapped in a Speculative Trade
The clinical result itself is genuinely significant. A vaccine that’s individually sequenced to a patient’s own tumor and shown to measurably delay melanoma’s return is a real step forward, and the researchers, trial participants, and clinicians behind it earned the headline. But the stock move that followed wasn’t really a reaction to melanoma patients getting a better outcome. It was a reaction to a company that had lost nearly 94 percent of its 2021 peak value suddenly having a plausible new commercial pipeline again, after four straight down years built almost entirely on a shrinking COVID vaccine business. That’s not cynicism, it’s just what the numbers show: the size of the pop was driven as much by Moderna’s need for a turnaround story as by the strength of the melanoma data itself.
The Access Question Nobody’s Answered Yet
Neither company has set a price for the vaccine, and manufacturing an individualized shot tailored to each patient’s specific tumor genetics is a fundamentally more expensive process than producing a standardized vaccine at scale. Moderna and Merck say they plan to file for regulatory approval within months and could bring the therapy to market as early as 2027, but pricing has not been part of any public statement so far. Historically, personalized and biologic cancer therapies in the US have launched with price tags well into six figures per course of treatment, and there’s no indication yet that this one will land differently.
That’s the part of this story that deserves as much scrutiny as the stock chart: a genuine medical breakthrough is only as good as who can actually access it once it’s approved.
Watch: Cancer Vaccine Shows Promise Against Melanoma
What do you think? Should regulators require a pricing commitment before approving breakthrough therapies like this one, or does that risk slowing down access to genuinely lifesaving treatment? Let us know your thoughts in the comments on BeezLoop.com!
